Oncosil has enough $ from the capital raising to complete the...

Oncosil has enough $ from the capital raising to complete the trial - which will then be published. That will take time - even though there are preliminary analyses along the way.

Remember that treatment of pancreatic cancer is rarely surgery (very extensive surgery and only if it is localised) and the other options are chemotherapy +/- radiotherapy.

The Oncosil treatment is the alternative to radiotherapy. Better to deliver it directly to the tumour than through from externally as theoretically less side effects.

The radiotherapy Oncosil treatment can be used in the same way as the Sirtex for liver cancers but delivery is easier as it is just by injection under imaging control as opposed to through the arteries like the Sirtex spheres.

In terms of future income - from the news release note:

"The Company also advises that it continues to make preparations for an Investigational Device Exemption (IDE) submission for OncoSil™ to the US Food and Drug Administration (FDA), and expects to submit an IDE in the near future. An IDE submission would represent a significant step in the regulatory pathway for OncoSil™, and is the the first step towards securing the FDA’s commercial approval for OncoSil™ under a Premarket Approval (PMA)."

Remember that Sirtex is still running its final trial... but it has a significant income from sale of the Sirex spheres outside of the trial.... I suspect that is what we will soon see from Oncosil, although regulations differ in USA, Europe and Australia... but you actually can sell the "device" before proof of effect. Some centres will only do the commercial sales and not trial - and some patients would rather just have and pay for the treatment - and not take a 1 in 3 chance of not getting the spheres.

I havent clarified this with the company - but that is how these products usually work, and it is how it is working for Sirtex...